首页> Clinical cancer research : an official journal of the American Association for Cancer Research> An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.

导出原文传递

翻译打印收藏纠错

第一作者： Rui,Wang

第一单位： Sanofi, Oncology Clinical Translational Medicine, Cambridge, Massachusetts.

作者： Rui,Wang ^[1] ; Chan,Gao ^[2] ; Megan,Raymond ^[2] ; Gennaro,Dito ^[3] ; Dominic,Kabbabe ^[3] ; Xiao,Shao ^[3] ; Ed,Hilt ^[3] ; Yongliang,Sun ^[3] ; Irene,Pak ^[3] ; Martin,Gutierrez ^[4] ; Ignacio,Melero ^[5] ; Anna,Spreafico ^[6] ; Richard D,Carvajal ^[7] ; Michael,Ong ^[8] ; Anthony J,Olszanski ^[9] ; Christina,Milburn ^[3] ; Kent,Thudium ^[3] ; Zheng,Yang ^[3] ; Yan,Feng ^[3] ; Paula M,Fracasso ^[10] ; Alan J,Korman ^[2] ; Praveen,Aanur ^[3] ; Shih-Min A,Huang ^[11] ; Michael,Quigley ^[12]

作者单位： Sanofi, Oncology Clinical Translational Medicine, Cambridge, Massachusetts. ^[1] Bristol-Myers Squibb, Discovery Oncology, Redwood City, California. ^[2] Bristol-Myers Squibb, Princeton, New Jersey. ^[3] Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. ^[4] Immunology and Immunotherapy Service, Center for Applied Medical Research, Clinica Universidad de Navarra, Pamplona, Spain. ^[5] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.;Department of Medicine, University of Toronto, Toronto, Canada.;Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. ^[6] Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, New York. ^[7] Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, Ontario, Canada. ^[8] Department of Hematology/Oncology, Fox Chase Cancer Center, Temple University, Philadelphia, Pennsylvania. ^[9] Adaptimmune LLC, Philadelphia, Pennsylvania. ^[10] AbbVie, Translational Oncology, Redwood City, California. ^[11] Bristol-Myers Squibb, Discovery Oncology, Redwood City, California. michael.quigley@bms.com. ^[12]